Atossa Therapeutics Inc., in collaboration with Insilico Medicine, has announced the publication of a joint study evaluating (Z)-endoxifen as a potential therapeutic candidate for glioblastoma multiforme (GBM). The results of the study, which utilized Insilico's AI-powered PandaOmics platform to systematically explore new oncology indications for endoxifen, have been published in Nature Scientific Reports. The study identified GBM as a top candidate for further investigation of (Z)-endoxifen, an active metabolite of tamoxifen with known activity in endocrine-resistant breast cancer. The announcement did not specify the initiation of a clinical trial, but highlighted the publication of these preclinical findings and the potential for future therapeutic programs.